Clinical Policy: Levoleucovorin (Fusilev, Khapzory)
Reference Number: CP.PHAR.151
Effective Date: 02.01.16
Last Review Date: 11.20
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Levoleucovorin (Fusilev®, Khapzory™) is a folate analog.

FDA Approved Indication(s)
Fusilev is indicated:
- For rescue after high-dose methotrexate (MTX) therapy in adult and pediatric patients with osteosarcoma
- For diminishing the toxicity with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients
- For the treatment of patients with metastatic colorectal cancer in combination with 5-fluorouracil (5-FU)

Khapzory is indicated:
- For rescue after high-dose MTX therapy in patients with osteosarcoma
- For diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination
- For the treatment of patients with metastatic colorectal cancer in combination with fluorouracil

Limitation(s) of use: Fusilev and Khapzory are not approved for pernicious anemia and megaloblastic anemias secondary to the lack of vitamin B₁₂. Improper use may cause a hematologic remission while neurologic manifestations continue to progress.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Fusilev and Khapzory are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Methotrexate/Folic Acid Antagonist Toxicity Prophylaxis (must meet all):
      1. Prescribed for one of the following uses (a, b, or c):
         a. Rescue after MTX therapy for osteosarcoma or an NCCN-recommended cancer (see Appendix D);
         b. Antidote for impaired MTX elimination;
         c. Antidote for accidental overdose of folic acid antagonists (including MTX);
2. Request is for Fusilev or Khapzory;
3. Age ≥ 6 years;
4. Member meets one of the following (a or b):
   a. Documentation supports contraindication or clinically significant adverse effects to leucovorin;
   b. Leucovorin is not available for use due to a national drug shortage documented on the FDA’s Drug Shortages Index (see Appendix D);
5. Request meets one of the following (a or b):*
   a. For Fusilev or Khapzory: Dose is appropriate and will be adjusted as necessary per section V;
   b. For Fusilev or Khapzory: Dose is supported by practice guidelines or peer-reviewed literature for the relevant use (prescriber must submit supporting evidence).

*Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:
Impaired elimination/accidental overdose: 1 month
High-dose MTX therapy rescue:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

B. Combination Chemotherapy with 5-FU (must meet all):
1. Prescribed for use in a fluorouracil-based chemotherapy treatment regimen for colorectal cancer or an NCCN-recommended cancer (see Appendix D);
2. Prescribed by or in consultation with an oncologist;
3. Request is for Fusilev or Khapzory;
4. Age ≥ 6 years;
5. Prescribed in combination with 5-FU;
6. Member meets one of the following (a or b):
   a. Documentation supports contraindication or clinically significant adverse effects to leucovorin;
   b. Leucovorin is not available for use due to a national drug shortage documented on the FDA's Drug Shortages Index (see Appendix D);
7. Request meets one of the following (a or b):*
   a. For Fusilev or Khapzory: Colorectal cancer: dose does not exceed regimen in section V;
   b. For Fusilev or Khapzory: Dose is supported by practice guidelines or peer-reviewed literature for the relevant use (prescriber must submit supporting evidence).

*Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

C. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is
II. Continued Therapy
   A. All Indications in Section I (must meet all):
      1. Member meets one of the following (a or b):
         a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
         b. Documentation supports that member is currently receiving the requested drug for high-dose MTX rescue as part of chemotherapy or combination chemotherapy with 5-FU and has received this medication for at least 30 days;
      2. Request is for Fusilev or Khapzory;
      3. Member is responding positively to therapy;
      4. Documentation supports contraindication or clinically significant adverse effects to leucovorin, or leucovorin continues to be unavailable due to a national drug shortage;
      5. If request is for a dose increase, request meets one of the following (a or b):*
         a. For Fusilev or Khapzory: New dose does not exceed regimen in section V;
         b. For Fusilev or Khapzory: New dose is supported by practice guidelines or peer-reviewed literature for the relevant use (prescriber must submit supporting evidence).
     *Prescribed regimen must be FDA-approved or recommended by NCCN

   Approval duration:
   Impaired elimination/accidental overdose: 1 month
   All other indications:
   Medicaid/HIM – 12 months
   Commercial – 6 months or to the member’s renewal date, whichever is longer

   B. Other diagnoses/indications (must meet 1 or 2):
      1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
      Approval duration: Duration of request or 6 months (whichever is less); or
      2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, and CP.PMN.53 for Medicaid and HIM-Medical Benefit.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, and CP.PMN.53 for Medicaid and HIM-Medical Benefit or evidence of coverage documents;
   B. Pernicious or megaloblastic anemia.
IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

5-FU: 5-fluorouracil  
FDA: Food and Drug Administration  
MTX: methotrexate  
NCCN: National Comprehensive Cancer Network

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
</table>
| leucovorin              | **MTX rescue**  
15 mg (~10 mg/m²) PO, IM, or IV given 24 hrs after MTX infusion, then every 6 hrs for 10 doses until MTX level is < 0.05 μM (dose may be adjusted based on elimination rates)  
**Folic acid antagonist overdose**  
5 to 15 mg PO QD  
**Colorectal cancer (or other combination chemotherapy with 5-FU*)**  
Varies | Varies |

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

*Off-label

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): previous allergic reactions attributed to folic acid or folinic acid
- Boxed warning(s): none reported

Appendix D: General Information

- The FDA’s Drug Shortages Index can be found at: www.accessdata.fda.gov/scripts/drugshortages/default.cfm.
- Per NCCN, 400 mg/m² of leucovorin is equivalent to 200 mg/m² of levoleucovorin.
- The NCCN guidelines recommend the combination use of levoleucovorin with methotrexate as a rescue for the following cancers (2A recommendation) when leucovorin is not available:
  - Acute lymphoblastic leukemia
  - T-cell lymphomas (including peripheral T-cell lymphomas, adult T-cell leukemia/lymphoma, extranodal NK/T-cell lymphoma [nasal type])
  - Bone cancer (including osteosarcoma, dedifferentiated chondrosarcoma, high-grade undifferentiated pleomorphic sarcoma, soft tissue sarcomas)
  - CNS cancer (including primary CNS lymphoma, brain metastases, leptomeningeal metastases)
○ B-cell lymphomas (including mantle cell lymphoma, AIDS-related B-cell lymphoma, Burkitt lymphoma, follicular lymphomas, high grade B-cell lymphomas, diffuse large B-cell lymphoma) Gestational trophoblastic neoplasia
○ Chronic lymphocytic leukemia and acute lymphoblastic leukemia

- The NCCN guidelines recommend the combination use of levoleucovorin with fluorouracil-based regimens for the following cancers (2A recommendation) when leucovorin is not available:
  ○ Thymomas and thymic carcinomas
  ○ Occult primary adenocarcinoma or squamous cell carcinoma
  ○ Mucinous carcinoma
  ○ Colon cancer
  ○ Gastric cancer
  ○ Esophageal and esophagogastric junction cancers
  ○ Anal carcinoma
  ○ Poorly differentiated (high grade)/large or small cell neuroendocrine and adrenal tumors
  ○ Cervical cancer
  ○ Leptomeningeal metastases
  ○ Rectal cancer
  ○ Hepatobiliary carcinoma
  ○ Pancreatic adenocarcinoma
  ○ Bladder cancer (non-urothelial and urothelial with variant histology)
  ○ Ovarian, fallopian tube, primary peritoneal cancer

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
</table>
| Rescue after high-dose MTX therapy in osteosarcoma | 7.5 mg (approximately 5 mg/m²) IV every 6 hours for 10 doses starting 24 hours after beginning of MTX infusion; adjust or extend rescue based on the following clinical situation and laboratory findings:  
  Normal MTX elimination (serum MTX 10 µM at 24 hours, 1 µM at 48 hours, and < 0.2 µM at 72 hours after administration): 7.5 mg IV every 6 hours for 60 hours (10 doses starting 24 hours after start of MTX infusion)  
  Delayed late MTX elimination (serum MTX > 0.2 µM at 72 hours and > 0.05 µM at 96 hours after administration): 7.5 mg IV every 6 hours until MTX < 0.05 µM  
  Delayed early MTX elimination and/or evidence of acute renal injury (serum MTX ≥ 50 µM at 24 hours, ≥ 5 µM at 48 hours, or ≥ 100% increase in serum creatinine at 24 hours after MTX administration): 75 mg IV every 3 hours until | See regimen |
### Indication | Dosing Regimen | Maximum Dose |
---|---|---|
MTX < 1 μM; then 7.5 mg IV every 3 hours until MTX < 0.05 μM | | |
If significant clinical toxicity is observed, Fusilev or Khapzory therapy should be extended for an additional 24 hours (total of 14 doses over 84 hours) in subsequent course of therapy. | | |
Inadvertent MTX overdose | Administer as soon as possible after overdose and within 24 hours of MTX administration if there is delayed excretion: 7.5 mg (approximately 5 mg/m²) IV every 6 hours until serum MTX is < 5 x 10^-8 M. Increase to 50 mg/m² IV every 3 hours if one of the following: • 24 hour serum creatinine has increased 50% over baseline • 24 hour MTX level is > 5 x 10^-6 M • 48 hour level is > 9 x 10^-7 M | See regimen |
Colorectal cancer | Regimens used historically include: • 100 mg/m² IV followed by 5-FU 370 mg/m² IV; or • 10 mg/m² IV followed by 5-FU 425 mg/m² IV | See regimen |
| Administer Fusilev or Khapzory, and 5-FU separately. Repeat Fusilev or Khapzory daily for 5 day course. Courses may be repeated at 4 week intervals for 2 courses, then repeated at 4 to 5 week intervals. | | |

### VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fusilev (levoleucovorin)</td>
<td>• Single-use vial with powder for reconstitution: 50 mg • Single-use vial with solution: 175 mg/17.5 mL, 250 mg/25 mL</td>
</tr>
<tr>
<td>Khapzory (levoleucovorin)</td>
<td>Single-use vial with powder for reconstitution: 175 mg and 300 mg</td>
</tr>
</tbody>
</table>

### VII. References

CLINICAL POLICY
Levoleucovorin


Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0641</td>
<td>Injection, levoleucovorin calcium, 0.5 mg</td>
</tr>
</tbody>
</table>

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th></th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy developed</td>
<td>01.16</td>
<td>02.16</td>
</tr>
<tr>
<td>Removed oncologist requirement. Added contraindication (allergy). Added “responding positively to therapy” under “Methotrexate/Folic Acid Antagonist Toxicity Prophylaxis” continuation criteria. Removed detailed language under CRC continuation criteria regarding whether member has recovered between successive regimens and replaced it with “no disease progression or unacceptable toxicity”. NCCN recommended uses added. Added formulations</td>
<td>02.17</td>
<td>02.17</td>
</tr>
<tr>
<td>Converted to new template. All indications: Removed allergy contraindication as it constitutes a hypersensitivity reaction. Modified leucovorin criteria to allow for clinically significant adverse effects. Added max dose criteria. Following MTX: Added age limit as safety and efficacy have not been established in patients &lt; 6 years. For impaired elimination/accidental overdose, decreased continued approval duration from 3 months to 1 month as these events do not occur chronically and are typically managed on an inpatient basis. For sarcomas, increased approval duration from 1/3 months to 6/12 months (MTX regimens used in bone cancers are dosed on a schedule through 45 weeks after surgery per MTX’s PI, while the NCCN guidelines do not indicate a limit on treatment duration).</td>
<td>08.08.17</td>
<td>11.17</td>
</tr>
</tbody>
</table>
**CLINICAL POLICY**

Levoleucovorin

---

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRC: Added NCCN off label recommended uses. Increased approval duration from 3/6 months to 6/12 months per new standard. Added megaloblastic and pernicious anemias as diagnoses not covered per PI.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4Q 2018 annual review: added new line of business - Commercial; specialist requirement added for combo use with 5-FU; added NCCN off-label recommended uses; summarized NCCN- and FDA-approved uses for improved clarity; added COC for 5-FU chemo combo use; references reviewed and updated.</td>
<td>08.14.18</td>
<td>11.18</td>
</tr>
<tr>
<td>4Q 2019 annual review: no significant changes; additional cancers amenable to rescue therapy added to Appendix D per NCCN; updated off-label dosing per new template; references reviewed and updated.</td>
<td>08.25.19</td>
<td>11.19</td>
</tr>
<tr>
<td>4Q 2020 annual review: modified HIM-Medical Benefit to HIM line of business; added Khapzory to policy; updated FDA approved indications for addition of pediatric use; references reviewed and updated.</td>
<td>08.13.20</td>
<td>11.20</td>
</tr>
</tbody>
</table>

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a
discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.